Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.93 USD | +1.77% |
|
+1.49% | +3.80% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.80% | 672M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau